MyoKardia_Logo_RGB.png
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
July 18, 2019 08:30 ET | MyoKardia, Inc.
EXPLORER-HCM Patient Screening Closes Ahead of Schedule – Initial Results Now Anticipated in the Second Quarter of 2020 Royalty Purchase Creates Additional Economic Value for MyoKardia’s Emerging HCM...
MyoKardia_Logo_RGB.png
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
June 24, 2019 08:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive...
MyoKardia_Logo_RGB.png
MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
June 18, 2019 16:05 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia_Logo_RGB.png
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
May 28, 2019 08:30 ET | MyoKardia, Inc.
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable...
MyoKardia_Logo_RGB.png
MyoKardia Reports First Quarter 2019 Financial Results
May 09, 2019 16:05 ET | MyoKardia, Inc.
Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 ...
MyoKardia_Logo_RGB.png
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 08, 2019 16:10 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
May 07, 2019 16:10 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular...
MyoKardia_Logo_RGB.png
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
May 02, 2019 08:00 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
April 30, 2019 08:30 ET | MyoKardia, Inc.
Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with...
MyoKardia_Logo_RGB.png
MyoKardia Announces Pricing of Public Offering of Common Stock
March 26, 2019 18:45 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...